BIVI Stock Summary and Trading Ideas (Biovie | NASDAQ:BIVI)

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Biovie trades on the NASDAQ stock market under the symbol BIVI.

As of April 6, 2026, BIVI stock price climbed to $1.47 with 81,864 million shares trading.

BIVI has a beta of 0.87, meaning it tends to be less sensitive to market movements. BIVI has a correlation of 0.01 to the broad based SPY ETF.

BIVI has a market cap of $11.08 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BIVI traded as high as $869.00 and as low as $1.06.

The top ETF exchange traded funds that BIVI belongs to (by Net Assets): VTI, VXF.

BIVI has underperformed the market in the last year with a return of -84.6%, while SPY returned +18.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BIVI shares. However, BIVI has outperformed the market in the last 3 month and 2 week periods, returning +10.5% and +0.7%, while SPY returned -3.3% and +0.4%, respectively. This indicates BIVI has been having a stronger performance recently.

BIVI support price is $1.35 and resistance is $1.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIVI shares will trade within this expected range on the day.